RxDoctor Payments Data

Eddy de Los Santos, MD

Psychiatry · Phoenix, AZNPI 1154409324

Payments from drug & device makers

$4,104in general payments, 2019–2025

Across 140 payments — averaging $29.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$901
  • Otsuka America Pharmaceutical, Inc.$835
  • Teva Pharmaceuticals USA, Inc.$600
  • Neurocrine Biosciences, Inc.$594
  • Johnson & Johnson$583
  • E.r. Squibb & Sons, L.L.C.$200
  • plus $391 from 4 others

What the payments were for

  • Food & beverage$4,07499%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,104 in reported general payments places this provider in the 85th percentile of 573 psychiatry providers in Arizona.

See all psychiatry providers in Arizona

Medicare billing

Part B allowed, 2024
$18,191
Medicare patients
17
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate116$416,588
Invega TrinzaPaliperidone Palmitate24$234,310
IngrezzaValbenazine Tosylate22$174,984
Abilify MaintenaAripiprazole46$136,347
AustedoDeutetrabenazine11$53,666
AristadaAripiprazole Lauroxil14$43,935
LybalviOlanzapine/Samidorphan Malate13$21,289
Divalproex Sodium ErDivalproex Sodium165$11,024
Aripiprazole31$7,272
Clozapine95$6,517
Fluphenazine Hcl84$4,460
Haloperidol Decanoate81$4,061
Olanzapine105$1,817
Benztropine Mesylate170$1,729
Risperidone112$1,477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$583$650,898140 claims
Neurocrine Biosciences, Inc.Ingrezza$594$174,98422 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$835$136,34746 claims
Alkermes, Inc.Aristada, Lybalvi$901$65,22427 claims
Teva Pharmaceuticals USA, Inc.Austedo$600$53,66611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 573 psychiatry providers in Arizona.

Other psychiatry in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →